Refine
Has Fulltext
- yes (4)
Is part of the Bibliography
- yes (4)
Document Type
- Journal article (3)
- Doctoral Thesis (1)
Keywords
- acute respiratory distress syndrome (4) (remove)
Institute
EU-Project number / Contract (GA) number
- 101003595 (1)
Background
Acute respiratory distress syndrome (ARDS) is a complex clinical diagnosis with various possible etiologies. One common feature, however, is pulmonary permeability edema, which leads to an increased alveolar diffusion pathway and, subsequently, impaired oxygenation and decarboxylation. A novel inhaled peptide agent (AP301, solnatide) was shown to markedly reduce pulmonary edema in animal models of ARDS and to be safe to administer to healthy humans in a Phase I clinical trial. Here, we present the protocol for a Phase IIB clinical trial investigating the safety and possible future efficacy endpoints in ARDS patients.
Methods
This is a randomized, placebo-controlled, double-blind intervention study. Patients with moderate to severe ARDS in need of mechanical ventilation will be randomized to parallel groups receiving escalating doses of solnatide or placebo, respectively. Before advancing to a higher dose, a data safety monitoring board will investigate the data from previous patients for any indication of patient safety violations. The intervention (application of the investigational drug) takes places twice daily over the course of 7 days, ensued by a follow-up period of another 21 days.
Discussion
The patients to be included in this trial will be severely sick and in need of mechanical ventilation. The amount of data to be collected upon screening and during the course of the intervention phase is substantial and the potential timeframe for inclusion of any given patient is short. However, when prepared properly, adherence to this protocol will make for the acquisition of reliable data. Particular diligence needs to be exercised with respect to informed consent, because eligible patients will most likely be comatose and/or deeply sedated at the time of inclusion.
Trial registration
This trial was prospectively registered with the EU Clinical trials register (clinicaltrialsregister.eu). EudraCT Number: 2017-003855-47.
Objectives
The severity of Coronavirus Disease 2019 (COVID-19) is largely determined by the immune response. First studies indicate altered lymphocyte counts and function. However, interactions of pro- and anti-inflammatory mechanisms remain elusive. In the current study we characterized the immune responses in patients suffering from severe COVID-19-induced acute respiratory distress syndrome (ARDS).
Methods
This was a single-center retrospective study in patients admitted to the intensive care unit (ICU) with confirmed COVID-19 between March 14th and May 28th 2020 (n = 39). Longitudinal data were collected within routine clinical care, including flow-cytometry of lymphocyte subsets, cytokine analysis and growth differentiation factor 15 (GDF-15). Antibody responses against the receptor binding domain (RBD) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike protein were analyzed.
Results
All patients suffered from severe ARDS, 30.8% died. Interleukin (IL)-6 was massively elevated at every time-point. The anti-inflammatory cytokine IL-10 was concomitantly upregulated with IL-6. The cellular response was characterized by lymphocytopenia with low counts of CD8+ T cells, natural killer (NK) and naïve T helper cells. CD8+ T and NK cells recovered after 8 to 14 days. The B cell system was largely unimpeded. This coincided with a slight increase in anti-SARS-CoV-2-Spike-RBD immunoglobulin (Ig) G and a decrease in anti-SARS-CoV-2-Spike-RBD IgM. GDF-15 levels were elevated throughout ICU treatment.
Conclusions
Massively elevated levels of IL-6 and a delayed cytotoxic immune defense characterized severe COVID-19-induced ARDS. The B cell response and antibody production were largely unimpeded. No obvious imbalance of pro- and anti-inflammatory mechanisms was observed, with elevated GDF-15 levels suggesting increased tissue resilience.
The interplay between inflammation and oxidative stress is a vicious circle, potentially resulting in organ damage. Essential micronutrients such as selenium (Se) and zinc (Zn) support anti-oxidative defense systems and are commonly depleted in severe disease. This single-center retrospective study investigated micronutrient levels under Se and Zn supplementation in critically ill patients with COVID-19 induced acute respiratory distress syndrome (ARDS) and explored potential relationships with immunological and clinical parameters. According to intensive care unit (ICU) standard operating procedures, patients received 1.0 mg of intravenous Se daily on top of artificial nutrition, which contained various amounts of Se and Zn. Micronutrients, inflammatory cytokines, lymphocyte subsets and clinical data were extracted from the patient data management system on admission and after 10 to 14 days of treatment. Forty-six patients were screened for eligibility and 22 patients were included in the study. Twenty-one patients (95%) suffered from severe ARDS and 14 patients (64%) survived to ICU discharge. On admission, the majority of patients had low Se status biomarkers and Zn levels, along with elevated inflammatory parameters. Se supplementation significantly elevated Se (p = 0.027) and selenoprotein P levels (SELENOP; p = 0.016) to normal range. Accordingly, glutathione peroxidase 3 (GPx3) activity increased over time (p = 0.021). Se biomarkers, most notably SELENOP, were inversely correlated with CRP (r\(_s\) = −0.495), PCT (r\(_s\) = −0.413), IL-6 (r\(_s\) = −0.429), IL-1β (r\(_s\) = −0.440) and IL-10 (r\(_s\) = −0.461). Positive associations were found for CD8\(^+\) T cells (r(_s\) = 0.636), NK cells (r\(_s\) = 0.772), total IgG (r\(_s\) = 0.493) and PaO\(_2\)/FiO\(_2\) ratios (r\(_s\) = 0.504). In addition, survivors tended to have higher Se levels after 10 to 14 days compared to non-survivors (p = 0.075). Sufficient Se and Zn levels may potentially be of clinical significance for an adequate immune response in critically ill patients with severe COVID-19 ARDS.
Das akute Lungenversagen des Erwachsenen (Acute Respiratory Distress Syndrome - ARDS) bleibt trotz lungenprotektiver Beatmung und dem Einsatz moderner Therapieverfahren ein schwerwiegendes Krankheitsbild mit nicht selten letalem Ausgang. Ziel der hier durchgeführten experimentellen Studien war es, sowohl den Einfluss verschieden hoher Niveaus des positiven end-exspiratorischen Drucks (PEEP) als auch die Auswirkungen einer unterschiedlichen Volumentherapie hinsichtlich Oxygenierung und histopathologischem Lungenschaden zu untersuchen. Hierzu wurde an 24 weiblichen narkotisierten und druckkontrolliert beatmeten Pietrain-Schweinen ein Lungenversagen mittels repetitiver bronchoalveolärer Lavage mit Kochsalzlösung induziert. Je acht Tiere wurden randomisiert und einer von drei Versuchsgruppen zugeteilt. In der ARDSNet(V+)-Gruppe wurde gemäß dem ARDS-Netzwerk mit einem festen Kombinationsschema aus PEEP und inspiratorischer Sauerstofffraktion (FiO2) beatmet und eine liberale Volumentherapie angewandt. In den Gruppen mit Open-Lung-Konzept (OLC) OLC(V+)- und OLC(V-) wurde eine Beatmung mit einem PEEP von 3 cm H2O über dem unteren Umschlagspunkt der Druck-Volumen-Kurve sowie Rekrutierungsmanövern von 50 cm H2O über 30 Sekunden durchgeführt. Die beiden OLC-Gruppen unterschieden sich im Hinblick auf die Volumensubstitution: restriktive Volumentherapie in OLC(V-) und liberale Volumentherapie in OLC(V+). Der Versuchszeitraum nach Randomisierung betrug 6,5 Stunden. Es wurden Gasaustausch- und Hämodynamikparameter zu fünf verschiedenen Messzeitpunkten ausgewertet. Des Weiteren wurden nach dem Versuchsende die Lungen histologisch untersucht. Bei der Untersuchung der Effekte der Beatmungsstrategien zeigte sich beim Vergleich der Gruppen mit großzügiger Volumensubstitution in der Gruppe mit höherem PEEP (OLC(V+)) eine bessere Oxygenierung (PaO2/FiO2 416+/-80 mmHg), verglichen mit der Beatmung gemäß ARDS-Netzwerk (ARDSNet(V+): PaO2/FiO2 189+/-55 mmHg). Ein statistisch signifikanter Unterschied im histopathologischen Lungenschaden zwischen beiden Gruppen konnte nicht gefunden werden (Gesamtscore OLC(V+) 1,6+/ [1,2-1,9] vs. ARDSNet(V+) 1,9 [1,4-2,0]). Bei der Untersuchung der Effekte der Volumentherapie konnte beim Vergleich der Gruppen mit Beatmung nach Open-Lung-Konzept in der Gruppe mit einem restriktiven Volumenmanagement (OLC(V-)) ein signifikant reduzierter histopathologischer Lungenschaden (Gesamtscore 0,9 [0,8-1,4]), jedoch keine weitere Verbesserung der Oxygenierung (PaO2/FiO2 400+/-55 mmHg) gegenüber der Gruppe mit liberalem Volumenmanagement (OLC(V+)) festgestellt werden. Zusammenfassend konnten wir mit unserer Studie zeigen, dass im experimentellen ARDS eine restriktive Volumentherapie den Lungenschaden reduzieren kann. Das Volumen-management scheint im experimentellen Lungenversagen somit einen größeren Einfluss auf den Lungenschaden zu haben als die Höhe des PEEP.